Key result
Tricuspid valve repair during left ventricular assist device implantation demonstrated comparable estimated survival to tricuspid valve replacement (p=0.88).
Why the study?
Does tricuspid valve repair compared to replacement result in different clinical outcomes in patients undergoing concomitant LVAD implant?
Cohort (n=126)
Does tricuspid valve repair compared to replacement result in different clinical outcomes in patients undergoing concomitant LVAD implant?
p-value: p=0.88
Tricuspid valve repair and replacement performed concomitantly with LVAD implantation yield comparable early and long-term clinical outcomes, including survival and TR reduction.
Comparable survival supports repair preference during LVAD implantation; leaves open need for randomized confirmation of equivalence.
INTRODUCTION: Severe tricuspid regurgitation (TR) is present in nearly half the patients undergoing implant of a left ventricular assist device (LVAD) and its correction confers better long-term outcome. AIM: To compare the early and late results of tricuspid valve repair (TVrpr) or replacement (TVR) with LVAD implant. PATIENT AND METHODS: Sixty-four from a cohort of 126 patients had a concomitant tricuspid valve procedure; 48 (75%) underwent a TVrpr whereas 16 (25%) had TVR. All preoperative hemodynamic parameters including the mean TR grade (TVrpr; 3.6 vs. TVR; 3.7) were comparable (p = 0.7). The mean TR grade was 1.6 ± 1.5 for the remaining 62 patients who did not have a concomitant tricuspid valve procedure, with 4/62 (6%) having severe TR (p < 0.0001). RESULTS: Cardiopulmonary bypass time was longer for patients undergoing TVR (p = 0.01). There was a significant reduction in right atrial pressure for the entire cohort (p < 0.01) and the postoperative right atrial pressure was not statistically different between TVrpr (13.6 ± 4.6) and TVR (11.6 ± 4.3; p = 0.6. Postoperative intensive care unit stay was comparable as was the duration of inotropic support (p = 0.5) or need for temporary right ventricular mechanical support. In-hospital mortality (12%) was not different between groups. The mean time for LVAD support was 12.3 ± 9.71 months and the last transthoracic echocardiographic examination was performed at mean intervals of 13.8 ± 10.8 months (TVrpr) and 11.8 ± 7.6 months (TVR; p = 0.47). Reduction in TR grade was similar between groups (p = 0.27). Late mortality (p = 1.00) was comparable in both groups. Using log-rank analysis, there was no significant difference in the estimated survival between TVrpr and TVR (p = 0.88). CONCLUSION: TVrpr repair at the time of LVAD implant is effective in correcting TR even at the end of one year of follow-up. The choice to repair or replace does not affect the clinical outcome.
No takes yet. Share an insight, caveat, or question.
Deo et al. (2012) conducted a cohort in Severe tricuspid regurgitation requiring left ventricular assist device (n=126). Tricuspid valve repair vs. Tricuspid valve replacement was evaluated on Estimated survival (p=0.88). Tricuspid valve repair during left ventricular assist device implantation demonstrated comparable estimated survival to tricuspid valve replacement (p=0.88).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: